middle.news
Imugene’s Azer-cel Achieves Complete Response in BTKi-Resistant Mantle Cell Lymphoma
10:00am on Wednesday 1st of July, 2026 AEST
•
Healthcare
Read Story
Imugene’s Azer-cel Achieves Complete Response in BTKi-Resistant Mantle Cell Lymphoma
10:00am on Wednesday 1st of July, 2026 AEST
Key Points
Second complete response in BTKi combination cohort
First Mantle Cell Lymphoma patient achieves remission post-BTKi failure
Azer-cel offers off-the-shelf CAR T therapy advantage
Trial ongoing across US and Australian sites
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Imugene (ASX:IMU)
OPEN ARTICLE